Literature DB >> 12514652

Quality of life and time trade-off utility measures in patients with coronary artery disease.

Kathryn A Melsop1, Derek B Boothroyd, Mark A Hlatky.   

Abstract

BACKGROUND: Contemporary clinical trials commonly measure quality of life and medical costs to establish whether therapies are both effective and cost effective. Cost-effectiveness analysis, however, requires a measure of patient utility or preferences for various health states. Because utilities are not often measured directly, we sought to develop a method of translating standard quality-of-life scales into a patient utility measure.
METHODS: Five hundred fifty-three patients enrolled in the Bypass Angioplasty Revascularization Investigation Study of Economics and Quality of Life completed a battery of quality-of-life measures and a time trade-off utility assessment an average of 7.3 years after random assignment.
RESULTS: The mean time trade-off score was 8.54 (SD = 2.53) out of a maximum of 10; median score was 9.95. The distribution of scores was skewed, with 12% of patients at the highest possible score of 10. Patients with recurrent angina had significantly lower time trade-off scores than patients without angina (mean 7.03 vs 8.70, P <.05). Time trade-off scores were moderately correlated with each quality-of-life measure (Spearman coefficients 0.38-0.52). Time trade-off scores could be predicted by combinations of 4 (r2 = 0.29), 5 (r2 = 0.31), or 6 (r2 = 0.32) variables.
CONCLUSIONS: Time trade-off utility scores can be inferred from commonly used quality-of-life measures. Angina significantly reduces patient utility scores.

Entities:  

Mesh:

Year:  2003        PMID: 12514652     DOI: 10.1067/mhj.2003.37

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  16 in total

Review 1.  Evaluation of content on EQ-5D as compared to disease-specific utility measures.

Authors:  Fang-Ju Lin; Louise Longworth; A Simon Pickard
Journal:  Qual Life Res       Date:  2012-06-23       Impact factor: 4.147

2.  Health-related quality of life and health utility for the institutional elderly in Taiwan.

Authors:  Kuan-Lang Lai; Rong-Jye Tzeng; Bing-Long Wang; Hong-Shen Lee; Roger L Amidon; Senyeong Kao
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

3.  Quality-of-life valuations of advanced breast cancer by New Zealand women.

Authors:  Richard J Milne; Kathy H Heaton-Brown; Paul Hansen; David Thomas; Vernon Harvey; Alison Cubitt
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Twenty-four-hour ambulatory blood pressure monitoring in hypertension: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2012-05-01

5.  Using existing data to identify candidate items for a health state classification system in multiple sclerosis.

Authors:  Ayse Kuspinar; Lois Finch; Simon Pickard; Nancy E Mayo
Journal:  Qual Life Res       Date:  2013-12-15       Impact factor: 4.147

6.  Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.

Authors:  Nick Bansback; Roberta Ara; Sue Ward; Aslam Anis; Hyon K Choi
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION).

Authors:  Kishan S Parikh; Adrian Coles; Phillip J Schulte; William E Kraus; Jerome L Fleg; Steven J Keteyian; Ileana L Piña; Mona Fiuzat; David J Whellan; Christopher M O'Connor; Robert J Mentz
Journal:  Am J Cardiol       Date:  2016-07-29       Impact factor: 2.778

8.  Systolic blood pressure and subjective well-being in patients with coronary artery disease.

Authors:  Yan Gong; Eileen M Handberg; Tobias Gerhard; Rhonda M Cooper-Dehoff; L Douglas Ried; Julie A Johnson; Carl J Pepine
Journal:  Clin Cardiol       Date:  2009-11       Impact factor: 2.882

9.  Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  Mark A Hlatky; Derek B Boothroyd; Kathryn A Melsop; Laurence Kennedy; Charanjit Rihal; William J Rogers; Lakshmi Venkitachalam; Maria M Brooks
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690

10.  Benefits and harms associated with hormone replacement therapy: clinical decision analysis.

Authors:  Cosetta Minelli; Keith R Abrams; Alex J Sutton; Nicola J Cooper
Journal:  BMJ       Date:  2004-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.